1.Development and Evaluation of an Immunochromatographic Kit for the Detection of Antibody to PLASMODIUM VIVAX Infection in South Korea.
Seung Kyu PARK ; Kil Whoan LEE ; Sung Hee HONG ; Dong Sup KIM ; John Hwa LEE ; Byung Hun JEON ; Won Sin KIM ; Ho Joon SHIN ; Seon Ho AN ; Hyun PARK
Yonsei Medical Journal 2003;44(4):747-750
Malaria is a major parasitic disease in tropical areas. Three to five hundred million people suffer from the disease and it kill a million people per year. Blood smear observation was developed for the diagnosis of malaria, but the examination needs skilled experts and exact diagnosis is time consuming. A kit based on immunochromatography can be a reliable and rapid method for clinical diagnosis, even in the hands of inexperienced personnel. However, all such currently developed kits can only diagnose P. falciparum malaria. In our previous report, the C-terminal region of P. vivax merozoite surface protein 1 (PvcMSP) was cloned and expressed in E. coli. In the present study, we developed an immunochromatographic kit using this PvcMSP for the diagnosis of specific antibody to P. vivax malaria in serum samples. The kit was used to examine sera from vivax malaria patients and non-malaria-infected person and the test showed 100% sensitivity (78/78) and 98.3% specificity (58/59). This result demonstrated that the immunochromatographic kit for P. vivax antibody detection is applicable for the rapid and precise diagnosis of P. vivax malaria.
Animals
;
Antibodies, Protozoan/*analysis
;
*Chromatography
;
Human
;
*Immunologic Techniques
;
Korea
;
Malaria, Vivax/*parasitology
;
Plasmodium vivax/*immunology
;
*Reagent Kits, Diagnostic/*standards
2.Seroprevalence of Plasmodium vivax in the Republic of Korea (2003-2005) using Indirect Fluorescent Antibody Test.
Tong Soo KIM ; Yoon Joong KANG ; Won Ja LEE ; Byoung Kuk NA ; Sung Ung MOON ; Seok Ho CHA ; Sung Keun LEE ; Yun Kyu PARK ; Jhang Ho PAK ; Pyo Yun CHO ; Youngjoo SOHN ; Hyeong Woo LEE
The Korean Journal of Parasitology 2014;52(1):1-7
Plasmodium vivax reemerged in the Republic of Korea (ROK) in 1993, and is likely to continue to affect public health. The purpose of this study was to measure levels of anti-P. vivax antibodies using indirect fluorescent antibody test (IFAT) in border areas of ROK, to determine the seroprevalence of malaria (2003-2005) and to plan effective control strategies. Blood samples of the inhabitants in Gimpo-si, Paju-si, and Yeoncheon-gun (Gyeonggi-do), and Cheorwon-gun (Gangwon-do) were collected and kept in Korea Centers for Disease Control and Prevention (KCDC). Out of a total of 1,774 serum samples tested, the overall seropositivity was 0.94% (n=17). The seropositivity was the highest in Paju-si (1.9%, 7/372), followed by Gimpo-si (1.4%, 6/425), Yeoncheon-gun (0.67%, 3/451), and Cheorwon-gun (0.19%, 1/526). The annual parasite incidence (API) in these areas gradually decreased from 2003 to 2005 (1.69, 1.09, and 0.80 in 2003, 2004, and 2005, respectively). The highest API was found in Yeoncheon-gun, followed by Cheorwon-gun, Paju-si, and Gimpo-si. The API ranking in these areas did not change over the 3 years. The seropositivity of Gimpo-si showed a strong linear relationship with the API of 2005 (r=0.9983, P=0.036). Seropositivity data obtained using IFAT may be useful for understanding malaria prevalence of relevant years, predicting future transmission of malaria, and for establishing and evaluating malaria control programs in affected areas.
Antibodies, Protozoan/*blood
;
Fluorescent Antibody Technique, Indirect
;
Humans
;
Incidence
;
Malaria, Vivax/*epidemiology
;
Plasmodium vivax/*immunology
;
Republic of Korea/epidemiology
;
Seroepidemiologic Studies
3.Procedure and clinical assessments of malariotherapy: recent experience in 20 HIV patients.
Xiaoping CHEN ; Binquan XIAO ; Huifang XU ; Wenjun SHI ; Kai GAO ; Jili RAO
Chinese Medical Journal 2003;116(7):1016-1021
OBJECTIVETo demonstrate the side effects of malariotherapy and to explore safe procedures in conduct of malariotherapy for human immunodeficiency virus (HIV) infected patients.
METHODSTwenty HIV/acquired immunodeficiency syndrome (AIDS) patients were selected for the study of malariotherapy and were intravenously infected with Plasmodia vivax to induce therapeutic malaria. Malaria was terminated with chloroquine after 10 - 20 malarial febrile episodes. Clinical assessments were made before (baseline), during (malarial phase) and after (post) termination of malaria. The density of Plasmodia in peripheral blood from the HIV/AIDS patients were compared to that from HIV-negative naturally infected malarial patients who donated the blood for the therapeutically induced malaria. CD(4) cell baseline levels were correlated to the severity of malarial symptoms and parasitemia.
RESULTSThere were no significant differences of Plasmodium density between the HIV/AIDS patients injected with P. vivax and the HIV-negative blood donors. However, it was found that the HIV-positive patients had milder malarial symptoms and parasitemia with progressively lower CD(4) cell baseline levels. All patients developed every day or every other day fever episodes with headache and shaking chill. These symptoms were well tolerated with the aid of anti-pyretic medications. Spleen and liver enlargement were seen in 15 of 20 and 4 of 20 patients respectively. Transitory liver effects with increase of serum glutamic-pyruvic transaminase were seen in 2 of 20 during malarial phase. Most patients experienced mild to medium anemia and 6 of 20 patients developed thrombocytopenia during malarial phase. All these side effects disappeared after termination of malaria or within one month thereafter. No complications occurred in these patients.
CONCLUSIONSTherapeutically induced acute vivax malaria was well tolerated in 20 HIV-positive subjects who represented a range of CD(4) cell levels from 1868/ micro l to 15/ micro l. Malariotherapy did not induce complications while increasing CD(4) cell levels in most treated HIV/AIDS patients (results published elsewhere).
Adult ; Animals ; CD4-Positive T-Lymphocytes ; Female ; HIV Infections ; therapy ; Humans ; Immunotherapy ; adverse effects ; methods ; Lymphocyte Count ; Malaria, Vivax ; immunology ; Male ; Plasmodium vivax ; immunology
4.Identification of Immunodominant B-cell Epitope Regions of Reticulocyte Binding Proteins in Plasmodium vivax by Protein Microarray Based Immunoscreening.
Jin Hee HAN ; Jian LI ; Bo WANG ; Seong Kyun LEE ; Myat Htut NYUNT ; Sunghun NA ; Jeong Hyun PARK ; Eun Taek HAN
The Korean Journal of Parasitology 2015;53(4):403-411
Plasmodium falciparum can invade all stages of red blood cells, while Plasmodium vivax can invade only reticulocytes. Although many P. vivax proteins have been discovered, their functions are largely unknown. Among them, P. vivax reticulocyte binding proteins (PvRBP1 and PvRBP2) recognize and bind to reticulocytes. Both proteins possess a C-terminal hydrophobic transmembrane domain, which drives adhesion to reticulocytes. PvRBP1 and PvRBP2 are large (> 326 kDa), which hinders identification of the functional domains. In this study, the complete genome information of the P. vivax RBP family was thoroughly analyzed using a prediction server with bioinformatics data to predict B-cell epitope domains. Eleven pvrbp family genes that included 2 pseudogenes and 9 full or partial length genes were selected and used to express recombinant proteins in a wheat germ cell-free system. The expressed proteins were used to evaluate the humoral immune response with vivax malaria patients and healthy individual serum samples by protein microarray. The recombinant fragments of 9 PvRBP proteins were successfully expressed; the soluble proteins ranged in molecular weight from 16 to 34 kDa. Evaluation of the humoral immune response to each recombinant PvRBP protein indicated a high antigenicity, with 38-88% sensitivity and 100% specificity. Of them, N-terminal parts of PvRBP2c (PVX_090325-1) and PvRBP2 like partial A (PVX_090330-1) elicited high antigenicity. In addition, the PvRBP2-like homologue B (PVX_116930) fragment was newly identified as high antigenicity and may be exploited as a potential antigenic candidate among the PvRBP family. The functional activity of the PvRBP family on merozoite invasion remains unknown.
Epitopes, B-Lymphocyte/*chemistry/genetics/*immunology
;
Female
;
Humans
;
Immunodominant Epitopes/chemistry/genetics/*immunology
;
Malaria, Vivax/immunology/*parasitology
;
Middle Aged
;
Plasmodium vivax/chemistry/genetics/*immunology
;
Protein Structure, Tertiary
;
Protozoan Proteins/chemistry/genetics/*immunology
;
Reticulocytes/*parasitology
5.ELISA detection of vivax malaria with recombinant multiple stage-specific antigens and its application to survey of residents in endemic areas.
Sera KIM ; Hye Jin AHN ; Tong Soo KIM ; Ho Woo NAM
The Korean Journal of Parasitology 2003;41(4):203-207
An ELISA was developed for the diagnosis of vivax malaria using multiple stage-specific recombinant antigens of Plasmodium vivax. The DNA from the whole blood of a malaria patient was used as template to amplify the coding regions for the antigenic domains of circumsporozoite protein (CSP-1), merozoite surface protein (MSP-1), apical merozoite antigen (AMA-1), serine repeat antigen (SERA), and exported antigen (EXP-1). Each amplified DNA fragment was inserted into pQE30 plasmid to induce the expression of His-tagged protein in Escherichia coli (M15 strain) by IPTG. His-tagged proteins were purified by Ni-NTA metal-affinity chromatography and used as antigens for ELISA with patient sera that were confirmed previously by blood smear examinations. When applied to patient sera, 122 (80.3%) out of 152 vivax malaria cases reacted to at least one antigen, while no reactions were observed with 128 uninfected serum samples. We applied this ELISA to the screening of 3, 262 civilian residents in endemic regions near the DMZ, which resulted in 236 positively detected (7.2%) cases. This method can be applied to serological diagnosis and mass screening in endemic regions, or can be used as a safety test for transfusion blood in endemic areas.
Animals
;
Antibodies, Protozoan/*blood
;
Antigens, Protozoan/genetics/*immunology
;
*Endemic Diseases
;
Enzyme-Linked Immunosorbent Assay/methods
;
Humans
;
Life Cycle Stages
;
Malaria, Vivax/*diagnosis/epidemiology/parasitology
;
Mass Screening
;
Plasmodium vivax/*growth & development/immunology
;
Recombinant Proteins/*immunology
;
Serologic Tests
6.Western blot diagnosis of vivax malaria with multiple stage-specific antigens of the parasite.
Eui Sun SON ; Tong Soo KIM ; Ho Woo NAM
The Korean Journal of Parasitology 2001;39(2):171-176
Western blot analysis was performed to diagnose vivax malaria using stage-specific recombinant antigens. Genomic DNA from the whole blood of a malaria patient was used as templates to amplify the coding regions for the antigenic domains of circumsporozoite protein (CSP-1), merozoite surface protein (MSP-1), apical merozoite antigen (AMA-1), serine repeat antigen (SERA), and exported antigen (EXP-1) of Plasmodium vivax. Each amplified DNA fragment was inserted into a pGEX-4T plasmid to induce the expression of GST fusion protein in Escherichia coli by IPTG. The bacterial cell extracts were separated on 10% SDS-PAGE followed by western blot analysis with patient sera which was confirmed by blood smear examination. When applied with patient sera, 147 (91.9%) out of 160 vivax malaria, 12 (92.3%) out of 13 falciparum malaria, and all 9 vivax/falciparum mixed malaria reacted with at least one antigen, while no reactions occurred with 20 normal uninfected sera. In the case of vivax malaria, CSP-1 reacted with 128 (80.0%) sera, MSP-1 with 102 (63.8%), AMA-1 with 128 (80.0%), SERA with 115 (71.9%), and EXP-1 with 89 (55.6%), respectively. We obtained higher detection rates when using 5 antigens (91.9%) rather than using each antigen solely (55.6-80%), a combination of 2 (76.3-87.5%), 3 (85.6-90.6%), or 4 antigens (89.4-91.3%). This method can be applied to serological diagnosis, mass screening in endemic regions, or safety test in transfusion of prevalent vivax malaria.
Animals
;
Antigens, Protozoan/*blood
;
Biological Markers/blood
;
*Blotting, Western
;
Human
;
Life Cycle Stages/immunology
;
Malaria, Vivax/*diagnosis
;
Mass Screening
;
Plasmodium vivax/*immunology
;
Recombinant Proteins/blood
;
Serologic Tests/methods
;
Support, Non-U.S. Gov't
7.Relationship between Antibody-Positive Rate against Plasmodium vivax Circumsporozoite Protein and Incidence of Malaria.
Hyeong Woo LEE ; Yoon Joong KANG ; Shin Hyeong CHO ; Byoung Kuk NA ; Jhang Ho PAK ; Ho Woo NAM ; Yun Kyu PARK ; Youngjoo SOHN ; Tong Soo KIM
The Korean Journal of Parasitology 2015;53(2):169-175
The relationship between anti-Plasmodium vivax circumsporozoite protein (CSP) antibody levels and the prevalence of malaria in epidemic areas of South Korea was evaluated. Blood samples were collected from inhabitants of Gimpo-si (city), Paju-si, and Yeoncheon-gun (county) in Gyeonggi-do (province), as well as Cheorwon-gun in Gangwon-do from November to December 2004. Microscopic examinations were used to identify malaria parasites. ELISA was used to quantitate anti-circumsporozoite protein (CSP) antibodies against P. vivax. A total of 1,774 blood samples were collected. The overall CSP-ELISA-positive rate was 7.7% (n=139). The annual parasite incidences (APIs) in these areas gradually decreased from 2004 to 2005 (1.09 and 0.80, respectively). The positive rate in Gimpo (10.4%, 44/425) was the highest identified by CSP-ELISA. The highest API was found in Yeoncheon, followed by Cheorwon, Paju, and Gimpo in both years. The positive rates of CSP-ELISA were closely related to the APIs in the study areas. These results suggest that seroepidemiological studies based on CSP may be helpful in estimating the malaria prevalence in certain areas. In addition, this assay can be used to establish and evaluate malaria control and eradication programs in affected areas.
Adolescent
;
Adult
;
Antibodies, Protozoan/*blood
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Humans
;
Incidence
;
Malaria, Vivax/*blood/*epidemiology/parasitology
;
Male
;
Middle Aged
;
Plasmodium vivax/*immunology/physiology
;
Prevalence
;
Protozoan Proteins/immunology
;
Republic of Korea/epidemiology
;
Seroepidemiologic Studies
;
Young Adult
8.CD8+ T-cell Activation in Mice Injected with a Plasmid DNA Vaccine Encoding AMA-1 of the Reemerging Korean Plasmodium vivax.
Hyo Jin KIM ; Bong Kwang JUNG ; Jin Joo LEE ; Kyoung Ho PYO ; Tae Yun KIM ; Byung il CHOI ; Tae Woo KIM ; Hajime HISAEDA ; Kunisuke HIMENO ; Eun Hee SHIN ; Jong Yil CHAI
The Korean Journal of Parasitology 2011;49(1):85-90
Relatively little has been studied on the AMA-1 vaccine against Plasmodium vivax and on the plasmid DNA vaccine encoding P. vivax AMA-1 (PvAMA-1). In the present study, a plasmid DNA vaccine encoding AMA-1 of the reemerging Korean P. vivax has been constructed and a preliminary study was done on its cellular immunogenicity to recipient BALB/c mice. The PvAMA-1 gene was cloned and expressed in the plasmid vector UBpcAMA-1, and a protein band of approximately 56.8 kDa was obtained from the transfected COS7 cells. BALB/c mice were immunized intramuscularly or using a gene gun 4 times with the vaccine, and the proportions of splenic T-cell subsets were examined by fluorocytometry at week 2 after the last injection. The spleen cells from intramuscularly injected mice revealed no significant changes in the proportions of CD8+ T-cells and CD4+ T-cells. However, in mice immunized using a gene gun, significantly higher (P<0.05) proportions of CD8+ cells were observed compared to UB vector-injected control mice. The results indicated that cellular immunogenicity of the plasmid DNA vaccine encoding AMA-1 of the reemerging Korean P. vivax was weak when it was injected intramuscularly; however, a promising effect was observed using the gene gun injection technique.
Animals
;
Antigens, Protozoan/administration & dosage/genetics/*immunology
;
CD8-Positive T-Lymphocytes/*immunology
;
COS Cells
;
Cercopithecus aethiops
;
Humans
;
Lymphocyte Activation
;
Malaria, Vivax/*immunology/parasitology
;
Membrane Proteins/administration & dosage/genetics/*immunology
;
Mice
;
Mice, Inbred BALB C
;
Plasmodium vivax/genetics/*immunology
;
Protozoan Proteins/administration & dosage/genetics/*immunology
;
Protozoan Vaccines/administration & dosage/genetics/*immunology
;
Vaccines, DNA/administration & dosage/genetics/*immunology
9.Case of Malarial Hepatitis by Plasmodium Vivax.
The Korean Journal of Gastroenterology 2010;56(5):329-333
Malarial infection is one of the most important tropical diseases, but also increasing in the temperate regions. Severe malaria with organ dysfunction is commonly associated with Plasmodium falciparum, but rarely with Plasmodium vivax. Malarial hepatitis is also unusual in P. falciparum and very rare in P. vivax. Only 3 cases of malarial hepatitis caused by P. vivax have been reported in the world. Because the presence of hepatitis in malaria indicates a more severe illness with higher incidence of other complications and poor prognosis, malarial patients should be meticulously monitored for hepatic dysfunction with or without jaundice. We report here a case of malarial hepatitis caused by P. vivax that was presented by fever, general ache, nausea, fatigue, and significant elevation of aminotransferase and bilirubin.
Abdomen/ultrasonography
;
Antimalarials/therapeutic use
;
Erythrocytes/immunology/parasitology
;
Fatigue/etiology
;
Hepatitis/*diagnosis/etiology/ultrasonography
;
Humans
;
Malaria, Vivax/complications/*diagnosis/drug therapy
;
Male
;
Mefloquine/therapeutic use
;
Nausea/etiology
;
Plasmodium vivax/isolation & purification
;
Primaquine/therapeutic use
;
Young Adult
10.Probability of Antibody Formation against Circumsporozoite Protein of Plasmodium vivax among Korean Malaria Patients.
Ho Woo NAM ; Kyoung Ju SONG ; Hye Jin AHN ; Zhaoshou YANG ; Chom Kyu CHONG ; Pyo Yun CHO ; Seong Kyu AHN ; Tong Soo KIM
The Korean Journal of Parasitology 2014;52(2):143-149
To evaluate the seroprevalence against circumsporozoite protein (CSP) of Plasmodium vivax in sera of Korean patients, the central repeating domain (CRD) of CSP was cloned and analyzed. From the genomic DNA of patient's blood, 2 kinds of CSPs were identified to belong to a VK210 type, which is the dominant repeating of GDRA(D/A)GQPA, and named as PvCSPA and PvCSPB. Recombinantly expressed his-tagged PvCSPA or PvCSPB in Escherichia coli reacted well against sera of patients in western blot, with the detecting rate of 47.9% (58/121), which included 15 cases positive for PvCSPA, 6 cases positive for PvCSPB, and 37 cases for both. The mixture of PvCSPA and PvCSPB was loaded to a rapid diagnostic test kit (RDT) and applied with the same set of patient sera, which resulted in detection rates of 57.0% (69/121). When the protein sequences of PvCSPA were compared with those of P. vivax in endemic regions of India and Uganda, they were compatibly homologous to PvCSPA with minor mutations. These results suggested that the recombinant PvCSPA and PvCSPB loaded RDT may be a milestone in latent diagnosis which has been a hot issue of domestic malaria and important for radical therapy in overlapped infections with P. falciparum in tropical and subtropical areas. During the biological process of malarial infection, exposure of CSP to antigen-antibody reaction up to 57.0% is the first report in Korea.
Amino Acid Sequence
;
Antibodies, Protozoan/*blood/immunology
;
Antibody Formation
;
Antigens, Protozoan/immunology
;
Base Sequence
;
Humans
;
India
;
Malaria, Vivax/*diagnosis/*epidemiology/immunology
;
Merozoite Surface Protein 1/genetics/*immunology
;
Plasmodium vivax/genetics/immunology
;
Protozoan Proteins/genetics/*immunology
;
Reagent Kits, Diagnostic
;
Recombinant Proteins/diagnostic use/immunology
;
Republic of Korea/epidemiology
;
Sequence Analysis, DNA
;
Seroepidemiologic Studies
;
Uganda